drugset / Trial / NCT04655625
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
Phase 2/3
Completed
500 enrolled
AnGes, Inc.
Japan Agency for Medical Research and Development · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
Timeline
- Start
- 2020-11-23
- Primary completion
- 2021-04-02
- Completion
- 2022-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AG0302-COVID19 | Vaccine | 2 mg | Intramuscular |